Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Inthera Bioscience logo — Advancing the future of cancer treatment with innovative sma...

Inthera Bioscience

Advancing the future of cancer treatment with innovative small molecule therapies using proprietary technology, headquartered in Zürich.

Founded 2013 2-10 employees Series A Total: $18.60M Biotechnology, Health Care +1

General Information

Company Name Inthera Bioscience
Founded Year 2013
Employees 2-10
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Inthera Bioscience. To contact Inthera Bioscience, visit intherabio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Inthera Bioscience compare?

A PDF of Inthera Bioscience and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Inthera Bioscience soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Inthera Bioscience

Inthera Bioscience is a Swiss biopharmaceutical enterprise, established in 2013, with a primary focus on developing targeted small molecule therapies for solid tumors. Their innovative approach revolves around creating inhibitors of intracellular protein-protein interactions through a proprietary technology platform. The company is headquartered in Zürich, Switzerland and has garnered significant attention in the biotechnology, healthcare, and pharmaceutical industries. Their commitment to advancing the future of cancer treatment has attracted a notable €4.70M Series A investment on 26 June 2018, with the participation of esteemed investors such as Novo Holdings, Aglaia Biomedical Ventures, and MERL Ventures Fund. With its promising approach and robust investor backing, Inthera Bioscience brings a unique proposition to the forefront of cancer therapeutics.

Business keywords: Biopharmaceutical, Cancer Treatment, Small Molecule Therapies, Solid Tumors, Innovative Technology, Protein-Protein Interactions, Targeted Therapies, Drug Development, Precision Medicine, Switzerland, Zürich, Inthera Bioscience

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €4.70M 3
Novo Holdings Aglaia Biomedical Ventures MERL Ventures Fund
Novo Holdings, Aglaia Biomedical Ventures +1
26 Jun 2018
Series A Fr.10.50M 3
Novo Holdings Aglaia Biomedical Ventures MERL Ventures Fund
Novo Holdings, Aglaia Biomedical Ventures +1
31 May 2017
Seed Round €3.40M 4
Novo Holdings Aglaia Biomedical Ventures Microsoft Accelerator
Novo Holdings, Aglaia Biomedical Ventures +2
14 Dec 2015

Inthera Bioscience Alternatives & Competitors

View All Alternatives
Inthera Bioscience vs
AmpliMed Corporation
AmpliMed Corporation

Innovative oncology therapies paving the way for advanced cancer treatment

Venture round
Biotechnology, Health Care
Inthera Bioscience vs
Advenchen Laboratories, LLC
Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...

Venture round
6 employees
Biotechnology, Health Care
Inthera Bioscience vs
S*Bio
S*Bio

Pioneering the future of cancer treatment through innovative small molecule drugs.

Private Equity
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Inthera Bioscience

Advancing the future of cancer treatment with innovative small molecule therapies using proprietary technology, headquartered in Zürich.
Inthera Bioscience was founded in 2013.
Inthera Bioscience operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceutical, Cancer Treatment, Small Molecule Therapies and Solid Tumors.
Inthera Bioscience has approximately 2-10 employees.
Inthera Bioscience has completed 3 funding rounds, raising a total of $18.60M. The latest funding stage is Series A.
Top alternatives and competitors to Inthera Bioscience include AmpliMed Corporation, Advenchen Laboratories, LLC, S*Bio, Corridor Pharmaceuticals, Inc., Tagworks Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inthera Bioscience and AmpliMed Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Inthera Bioscience, https://bouncewatch.com/company/inthera-bioscience, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes